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BACKGROUND: In Sub-Saharan Africa, the fight against tuberculosis (TB) has encountered a great 
challenge because of the emergence of drug resistant TB strains and the high prevalence of HIV 
infection. The aim of this meta-analysis was to determine the association of drug-resistant TB with anti-
TB drug treatment history and HIV co-infection.  
METHODS: After electronic based literature search in the databases of Medline, HINARI, EMBASE 
and the Cochrane library, article selection and data extraction were carried out. HIV co-infection and 
previous history of TB treatment were used as predictors for the occurrence of any anti-TB drug resistant 
or multiple drug resistant TB (MDR-TB). The risk ratios for each included study and for the pooled 
sample were computed using the random-effects model. Heterogeneity test, sensitivity analyses and 
funnel plots were also done.   
RESULTS: The pooled analysis showed that the risk of developing drug-resistant TB to at least one anti-
TB drug was about 3 times higher in individuals who had a previous history of anti-TB treatment than 
new TB cases. The risk of having MDR-TB in previously anti-TB treated TB cases was more than 5-fold 
higher than that of new TB cases. Resistance to Ethambutol and Rifampicin was more than fivefold 
higher among the previously treated with anti-TB drugs. However, HIV infection was not associated with 
drug-resistant TB.  
CONCLUSION: There was a strong association of previous anti-TB treatment with MDR-TB. Primary 
treatment warrants special emphasis, and screening for anti-TB drugs sensitivity has to be strengthened.   





Tuberculosis (TB) and HIV co-infection continues 
to be one of the major public health problems in 
Sub-Saharan Africa (SSA). Since 1990, the 
number of people falling ill and dying of TB has 
been declining very slowly (1). But among 
infectious diseases, following HIV infection, TB is 
still the second leading cause of death worldwide 
and the first leading cause of death among HIV 
infected patients (2). In African region, the 
number of deaths caused by TB (including deaths 
of HIV-positive people) in the year 2010 was 
estimated to be 254, 000 (2).  
Since TB and HIV infections interact 
synergistically (3), the efforts to alleviate 
morbidities and mortalities due to TB have been 
facing challenges. The presence of HIV infection 
in TB infected persons (asymptomatic) accelerates 
the chance of developing TB disease and 
similarly, TB hastens HIV disease advancement 
(3).
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In 2010, from the 8.8 million incidences of TB 
cases, about 13% were HIV co-infected; of HIV 
co-infected, the African region alone contributed 
for 82% (2). Besides HIV, the fight against TB has 
encountered a great challenge by the widely 
spreading and emerging drug resistant TB 
infections (4). Globally, in 2010, 3.4% of new TB 
cases were estimated to be multidrug resistant 
(MDR-TB) (4). Though the number of surveys 
was small, data from some SSA countries 
indicated that the proportion of resistant TB 
(resistant to any anti-TB drugs or MDR) was 
lower than in Eastern Europe and some Asian 
countries, but South Africa was an outlier (5).  
Resistant TB strains can be acquired or new 
resistant TB strains can emerge due to different 
factors: previous use of quinolones (6), 
inappropriate TB treatment (7), poor adherence to 
anti-TB drugs, long-lasting illnesses, previous TB 
treatment (8, 9).  Very recently, WHO concluded 
that people living with HIV are facing the 
emerging threats of drug resistant TB (4), which 
was also noted in another report (10).  
Nevertheless, most studies emphasized the role of 
HIV and previous TB treatment in the 
development of drug resistant TB infection.  
The existing primary studies in SSA that 
assessed the association of anti-TB drug resistant 
TB with HIV lack consistency: some studies 
showed association of drug-resistant TB with HIV 
infection (11-13) while others reported no 
association with HIV (14-20). Additionally, in 
2008, a multi-study analysis that included seven 
SSA studies (all conducted before the year 2000) 
could not demonstrate an overall association of 
drug-resistant TB with HIV infection (21). 
However, the majority of the studies that assessed 
the association of drug-resistant TB with previous 
history of anti-TB drug treatment reported a 
statistically significant association (15-17, 20, 22).  
To date, there is no published meta-analysis 
that included the most recent studies exclusively 
in SSA, which have assessed the association of 
HIV and anti-TB drug treatment history with 
drug-resistant TB. Thus, the primary aim of this 
meta-analysis is to determine how strongly drug-
resistant TB was associated with anti-TB drug 
treatment history and HIV co-infection.  
METHODS 
Search strategy: After the authors reached 
agreement on the objectives and the possible 
search terms to be used, a computer based 
literature search was conducted by two of the 
authors independently. Databases that were 
searched include: Medline, HINARI, EMBASE 
and the Cochrane library. The search was further 
strengthened by searching any missed literatures 
with Google scholar search engine and by 
searching the reference list of relevant articles. 
Our search terms include: “Resistant TB”, “MDR-
TB”, “XDR-TB”, “HIV”, “Africa”, “Sub-Saharan 
Africa” and the names of Sub-Saharan African 
countries.  
Inclusion criteria and study selection: The 
predetermined inclusion criteria for this meta-
analysis were: 1) studies conducted in Sub-
Saharan Africa, 2) either longitudinal/cohort or 
cross-sectional studies which assessed the 
association of anti-TB drug resistant tuberculosis 
with HIV and/or anti-TB drug treatment history 
and 3) studies written in English. These criteria 
were set because the aim of this study was to 
assess the association of drug resistant TB with 
previous anti-TB drug exposure and HIV 
infection.  
Article selection was performed in two 
stages: first, after the titles and abstracts of the 
retrieved articles were reviewed, they were 
grouped as “likely” and “unlikely”. Second, the 
contents of articles grouped as “likely” by both 
authors and articles that were not selected by both 
authors (one author grouped them as “likely” and 
the other as “unlikely”) were reviewed in detail 
before the final decisions. If the two reviewers 
were still unable to decide whether to include or 
exclude a particular study, the conflict was 
resolved by a discussion involving the third 
author. 
Data extraction: Excel spreadsheet was used by 
both authors to extract the data. The extracted data 
included: author, year of publication, event time, 
country where the study was conducted, total 
number of HIV positives, number of HIV 
positives co-infected with any drug resistant TB, 
number of HIV positives co-infected with MDR-
TB, total number of HIV negatives, number of 
HIV negatives infected with any anti-TB drug 
resistant TB, number of HIV negatives infected 
with MDR-TB, total number of TB infected 
individuals with no previous history of anti-TB 
drug treatment, number of any anti-TB drug 
resistant TB infected individuals with no previous 




history of anti-TB drug treatment, number of 
MDR-TB infected individuals with no previous 
history of anti-TB drug treatment, total number of 
TB infected individuals with previous history of 
anti-TB drug treatment, number of any anti-TB 
drug resistant TB infected individuals with 
previous history of anti-TB drug treatment and 
number of MDR-TB infected individuals with 
previous history of anti-TB treatment.  
Operational definitions: In this meta-analysis, we 
used the term “any anti-TB drug resistance TB” to 
mean resistant TB to one or more anti-TB drugs. 
“MDR-TB” means that TB is resistant to at least 
isoniazid and rifampicin (1). Those grouped as 
“Individuals with previous history of anti-TB drug 
treatment” include: relapse, failures and return to 
treatment. In the meta-analysis that compared new 
and previously anti-TB drug treated cases, their 
HIV status could be either negative or positive. 
Similarly, in HIV positives and negatives TB 
drug-resistance comparison, the included 
individuals can be new or previously treated TB 
cases. 
Statistical analysis: The associations of any drug-
resistant TB and MDR-TB with HIV and anti-TB 
drug treatment history were meta-analyzed 
separately (anti-TB drug resistant TB in HIV 
positives VS anti-TB drug resistant TB in HIV 
negatives; MDR-TB in HIV positives VS MDR-TB 
in HIV negatives; any anti-TB drug resistant TB in 
previously anti-TB treated VS any anti-TB drug 
resistant TB in new TB cases and MDR-TB in 
previously anti-TB drug treated VS MDR-TB in 
new TB cases). Meta-analysis was also done for 
individual first line anti-TB drugs in relation to TB 
treatment history and HIV status. The overall risk 
ratios were determined with the DerSimonian-
Laird method (random-effects model).  
The heterogeneity among the studies was 
assessed by computing values for chi-square (Q), 
I
2
 and p-values. I
2 
≥ 50% was considered as 
statistically significant. Since the included studies 
were conducted with different setups, and because 
patients differed in their experience for 
antiretroviral therapy, we preferred to report the 
results of random effects model even in cases of 
insignificant heterogeneity. Furthermore, some 
patients who were grouped as anti-TB experienced 
could be cases of reinfection or relapse cases that 
will increase the heterogeneity of the included 
studies.  
To reveal the change in drug resistant TB 
with time, sub-group analyses based on study 
periods were carried out (studies before the year 
2000 vs studies after 2000). Sensitivity analyses 
(leaving one study out at a time) were conducted 
to estimate the stability of the overall risk ratios in 
the withdrawal of any studies from the analysis. 
Publication/disclosure biases were assessed with 
funnel plots. All the statistical analyses and plots 





















Figure 1.  Flow diagram to show study selection process, Sub-Saharan Africa 
5,710 citations were identified 
5,413 were excluded after 
reviewing their titles 
297 articles were retrieved (160 by the 
first author and 137 by the second author) 191 were excluded after reviewing 
the titles and abstracts 
 92 were not directly related to our 
topic 
 62 reviews and expert opinions 
 37 duplicates 106 articles were accepted for entire 
document review  
30 articles were included in the final meta-analysis 
Following full document review 76 
articles were excluded 
  






Search Result: As summarized in Fig.1, the 
literature search with the chosen search terms 
initially identified 5,710 citations. Taking the 
articles’ title proximity to the objective of this 
study, 297 articles were retrieved. After 
rescreening the titles and reviewing the abstracts, 
106 of the retrieved articles were accepted for 
detailed document review. Finally, 30 articles met 
the inclusion criteria for this meta-analysis (11-20, 
22, 23-41). However, all the selected articles were 
not included in every meta-analysis. The age range 
of study participants in the included studies was 
11 years – 86 years.  
HIV Infection and Drug Resistance TB: 
Specifically to determine the association of HIV 
infection with drug resistant TB meta-analysis, 
only 20 articles were included (with overall 3,371 
HIV infected and 3,937 HIV negative individuals). 
With the exception of two Ethiopian studies (11, 
12), all other studies showed no association of any 
anti-TB drug resistance to either HIV positives or 
HIV negatives, and the overall risk ratio (RR) was 
1.1 (95% CI, 0.92 to 1.23) (Fig 2). Sensitivity 
analysis attested the stability of the overall risk 
ratio; the overall RR swings between 1.01 and 
1.06. The test for heterogeneity did not show a 
significant variation among the twenty studies (I
2
 
= 23%). Likewise, the funnel plots did not show 




Figure 2. Risk ratio of any anti-TB drug resistance in relation to HIV status (HIV positives vs HIV negatives), a meta-
analysis in Sub-Saharan Africa. 




HIV Infection and MDR TB: The meta-analysis 
of MDR-TB did not also demonstrate a 
statistically significant association of MDR-TB 
with HIV co-infection. As presented in Fig.3, 
except for two studies (from Swaziland and 
Mozambique) (23, 33), all other studies showed 
the association of MDR-TB to HIV positives or 
HIV negatives with an overall RR of 1.0 and 95% 
CI, 0.78 to 1.36. When any of the studies were 
withdrawn from the analysis, the overall risk ratio 
ranged between 0.94 and 1.06.  
Heterogeneity testing showed only a 
moderate degree of variation among the studies (I
2
 
= 32%).  
  
Figure 3. Risk ratio of multidrug resistant TB (MDR-TB) in relation to HIV status (HIV positives vs HIV negatives), a 
meta-analysis in Sub-Saharan Africa.  
  





Previous Anti-TB Treatment and Drug 
Resistant TB: However, drug resistant TB was 
found to be significantly associated with a 
previous history of anti-TB drug treatment. The 
risk of having TB that was resistant to at least one 
anti-TB drug was about 3 times higher in 
individuals with a previous history of anti-TB 
treatment. As shown in Fig 4, with the exception 
of the studies by Nunes et al, Mulenga et al, and 
Bruchfeld et al (22, 31, 36), all others (with an 
overall RR of 2.9 and 95% CI, 2.38 to 3.46) 
demonstrated a significant association of anti-TB 
drug resistance with a previous history of 
exposure to anti-TB drugs. But heterogeneity 
testing revealed the presence of a significant 
variation among the studies (I
2
 = 72%). Sub-group 
analysis based on the period of data collection 
(before 2000 vs after 2000) did not show a 
significant variation in anti-TB drug resistance. 
Sensitivity analysis showed that the overall RR 
changed by about 0.1 at maximum with the 




Figure 4. Risk ratio of any anti-TB drug resistance in relation to previous history of anti-TB treatment (previously TB 
treated vs New TB cases), a meta-analysis in Sub-Saharan Africa. 




Previous Anti-TB Treatment and MDR TB: 
The risk of having MDR-TB in previously anti-TB 
treated individuals was more than five- fold higher 
than that of new TB cases (overall RR = 5.7; 95% 
CI, 3.61 to 8.96). Accordingly, the association of 
MDR-TB with previous anti-TB drug treatment 
was even stronger than those who had at least one 
drug-resistant TB. Even if fourteen of the sixteen 
studies and the pooled value showed a statistically 
significant association of MDR-TB with previous 
history of anti-TB drug treatment, two studies 
from Mozambique (14, 22),
 
one study from 
Zambia (31)
 
and one study from Ethiopia (36) 
were exceptions. Additionally, heterogeneity 
testing uncovered a significant variation among 
the included studies (I
2 
= 75%). But the sensitivity 





Figure 5. Risk ratio of multidrug resistant TB (MDR-TB) in relation to previous history of anti-TB treatment 
(previously TB treated vs New TB cases), a meta-analysis in Sub-Saharan Africa   
 





Resistance to First Line Anti-TB Drugs: Table 1 
summarizes several meta-analyses done on the 
association of individual first line anti-TB drug 
resistance with anti-TB drug treatment history and 
HIV status. Statistically significant resistance was 
found in four of the first line anti-TB drugs among 
previously treated anti-TB drug treated 
individuals, but a very strong association was seen 
in ethambutol and rifampicin (the overall RR = 5.8 
and 5.3, respectively). However, there was no 
increased risk of the selected first line anti-TB 
drug resistance by being HIV positive.      
 
Table 1: Overall risk ratios of first line anti-TB drugs resistance in relation to previous history of anti-TB 
drug treatment or HIV status, a meta-analyses in Sub-Saharan Africa 
 
 
TB Resistance predictor 











By anti-TB treatment 
history: 
    
        Isoniazid 3.22 2.45 - 4.24 80% 12 
        Rifampicin 5.25 3.27 -  8.37 80% 12 
        Streptomycin 2.68 1.89 - 3.82 75% 10 
        Ethambutol 5.81 3.35 - 10.05 64% 10 
By HIV status:     
       Isoniazid 0.99 0.81 – 1.22 0% 4 
       Rifampicin 1.02 0.52 – 2.00 55% 4 
       Streptomycin 1.09 0.75 – 1.59 42% 3 
       Ethambutol 0.81 0.16 – 4.11 52% 3 




This meta-analysis, which included mainly 
recently published studies, has demonstrated that 
the risk of developing single anti-TB drug 
resistance or MDR-TB was strongly associated 
with a previous history of exposure to anti-TB 
drugs, which is consistent with  another meta-
analysis that included studies conducted in the 
1990s (21). A similar report also came from 
mainland China (8). The 2002-2007 global survey 
conducted by WHO also showed that the highest 
prevalence of MDR-TB among newly diagnosed 
and previously treated TB cases was 22% and 
60%, respectively (5). The consistent findings 
across decades in the majority of studies and in 
this meta-analysis probably indicate how much the 
Mycobacterium TB is predisposed to develop 
resistance when it is exposed to anti-TB drugs. 
This may be related to poor patient’s adherence to 
treatment schedule, as previous reports showed 
(8).   
However, several questions need to be 
answered before a cause and effect conclusion can 
be made. First, despite our extensive search of 
electronic databases for studies in the region, we 
found no studies that assessed the presence of 
vertical (resistance to the same drug exposed to 
before) or horizontal drug resistance (cross 
resistance developed after exposure to any of the 
other anti-TB drugs before) using the 
Mycobacterium TB strains database. In other 
words, had this evidence been found in studies 
that compared the sensitivity pattern of the TB 
strain for the first line drugs in the initial infection 
with the TB strain in the repeated infection, one 
could ascertain the direct cause of previous 
treatment for vertical and/or cross resistance in the 
included studies.  
Otherwise, in some of the TB patients 
diseased for the second time, their previous 
treatment might have been counted wrongly as a 
risk factor for the developed resistance while the 
real story is that they were initially infected with a 
resistant TB strain. The same is true for 
reinfection: the initial infection might have been 
cured but the second time the patient could have 
acquired a resistant TB strain, in which the 
previous treatments was wrongly given credit for 
the development of drug resistance among 
reinfected patients. Similarly, the new TB cases, 
which were found to have a lesser degree of drug 




resistance, probably had an equal chance of 
acquiring resistant TB strains. Furthermore, this 
meta-analysis has shown that the association of 
MDR-TB with previous TB drug treatment was 
stronger than any anti-TB drug resistance, which 
probably indicates the possibility of acquiring 
resistant TB strains in the initial infection or the 
increased probability of cross resistance. It was 
also reported that patients infected by drug-
resistant TB and treated with short course 
chemotherapy are likely to acquire resistance 
through inadvertent monotherapy, the so called 
“amplifier effect” (42). This is very likely to 
happen in SSA as sensitivity testing is not 
routinely done before initiating short course anti-
TB therapy.    
Second, the data set was also inadequate or 
not fit for meta-analysis in terms of the 
contribution of the anti-TB treatment pattern in the 
previous infection. Several of the studies 
compared the resistance of new TB and previously 
TB treated cases without further stratifying the 
initial treatment pattern by duration, adherence to 
anti-TB drugs, and defaulting from taking drugs, 
which were attributed as important risk factors for 
occurrence of resistance (7, 8).  
In the authors’ opinion, among others, 
establishing a Mycobacterium TB strains database 
at the regional level is a top priority. Such a 
database would definitely help in identifying the 
sensitivity pattern of initial and repeat TB 
infections, allowing the timely detection of 
resistant strains and the taking of appropriate 
actions. We guess such initiative will not be as 
costly as the second line therapy, the economic 
and social impact of increasingly spreading 
resistant TB strains in the region.  
Some years back, it was reported that 
Mycobacterium TB is more liable to undergo 
mutation when it is exposed to isoniazid and 
rifampicin than to streptomycin and many of the 
second line anti-TB drugs (43). Although it was 
not possible to make analysis on comparisons of 
TB strains drug sensitivity in the initial and repeat 
infections, the resistance pattern between new and 
repeat infections with regard to the individual anti-
TB drugs demonstrated that the strength of 
resistance association with previous TB drug 
treatment was very high in ethambutol and 
rifampicin, and low in streptomycin. The 
proportion of resistance to isoniazid in primary 
studies was the highest in both new and previously 
anti-TB treated cases. As a result, the RR was 
falsely the second lowest. Such high proportion of 
resistance to isoniazid in both new and previously 
treated anti-TB cases was probably because of its 
wide use as prophylaxis in HIV positives. 
Similarly, TB resistance to isoniazid is the most 
common type in the United States (44).  
Discussing the mechanism for the 
development of resistance for each drug is beyond 
the scope of this manuscript. However, when we 
look at the findings in the individual studies, fewer 
resistant cases were found with ethambutol in the 
new than in the previously TB treated cases (15-
17, 20, 23, 29, 31, 33, 39). Could its bacteriostatic 
nature (mycobacterial cell wall biosynthesis 
inhibition) explain why Mycobacterium TB strains 
became highly resistant to ethambutol among the 
previously treated? The challenge is that 
rifampicin (bactericidal and mycobacterial RNA 
polymerase enzyme inhibitor), which is thought to 
be the cornerstone of short-course chemotherapy, 
was almost equally ineffective in previously TB 
treated patients.  
On the other hand, HIV infection is a known 
risk factor for increased incidence of TB disease, 
particularly in SSA where the burden of HIV 
infection is so high (2). In this meta-analysis, 
however, HIV co-infection was not found to have 
a statistically significant association with anti-TB 
drug resistance, which is consistent with other 
studies (8, 21). This is in contrast to a report from 
about two decades ago, which showed that 90% of 
cases of MDR-TB occurred in HIV-co-infected 
patients (45). Similarly, in the United States, it 
was reported that HIV infection was associated 
with MDR-TB
 
(46). About fifteen years ago, 
Anastasis et al expressed concern regarding the 
development of drug-resistant TB as the HIV 
epidemic progressed (14). However, the current 
meta-analysis provides strong evidence to affirm 
that HIV co-infection may not have an influence 
on the development of anti-TB drug resistance. 
Additionally, with the exception of a report from 
Latvia and Ukraine, several reports from different 
parts of the world have shown that HIV infection 
has no statistically significant association with 
MDR-TB (47). 
HIV is known to suppress the human cellular 
immunity and shorten the period from TB 
infection to TB disease (48); however, as this 





analysis showed, the chance of developing drug-
resistant TB seems not to be related with 
immunity. Even a study that compared a culture 
conversion with treatment among HIV-positives 
and negatives in MDR-TB patients revealed that 
there was no difference in the proportion who 
converted based on HIV status (49).  
The core point needing to be underlined is 
that SSA (with the exception of some districts of 
South Africa) is characterized by a low prevalence 
of drug-resistant TB (5), and a high prevalence of 
both TB and HIV infections (3). Had HIV co-
infection been a strong factor for occurrence of 
drug-resistant TB, SSA would have taken the lead. 
The implication is 1) Several of HIV infected 
patients in SSA didn’t have a chance to acquire a 
drug-resistant Mycobacterium TB strain and 2) 
The mechanism for resistance development in 
Mycobacterium TB may not be related to the 
suppression of the host’s cellular immunity as 
resistance is the microorganisms’ self-defense 
mechanism.   
It should be noted that we are not suggesting 
that HIV-infection has no role in the epidemiology 
of drug-resistant TB. Being HIV infected is a risk 
for developing TB disease and is equally a risk for 
being diseased with resistant TB and spreading it 
to others who are susceptible. Therefore, although 
this meta-analysis and others did not demonstrate 
statistically significant associations of drug-
resistant TB with HIV infection, it is our 
understanding that HIV has a significant role in 
fueling the spread of drug-resistant TB by 
accelerating the progression from TB infection to 
TB disease.      
Some authors have referred to MDR-TB as 
‘the third epidemic” (third to HIV and TB) to 
show the increasing magnitude of drug resistant 
TB across the world
 
(50). This meta-analysis has 
also shown that previous anti-TB drug treatment 
had a strong association with the development of 
MDR-TB. One of the strengths of this meta-
analysis is the finding regarding the resistance 
pattern of individual anti-TB drugs. The RRs of 
drug resistance among previously TB treated cases 
were significantly higher in ethambutol and 
rifampicin than others. However, HIV infection 
has not been associated with an increased risk of 
anti-TB drug resistance. Nevertheless, the high RR 
of MDR-TB, ethambutol, and rifampicin among 
previously TB treated cases are a big warning for 
this region, where the proportion of TB cases is 
very high (47). This situation warrants timely 
detecting and finding appropriate treatment for 
drug-resistant TB cases, which would help curtail 
transmission to many HIV positive individuals in 
the region. 
As limitation, since most of the included 
studies didn’t report the number of relapse cases, 
treatment failure cases, patients’ ART status and 
HIV clinical stages, it was not possible to conduct 
meta-regression analysis and subgroup analysis to 
estimate their effect on the association of anti-TB 
treatment history and HIV infection with drug 
resistant TB.  
This meta-analysis has demonstrated that the 
risk of developing single anti-TB drug resistance 
or MDR-TB was strongly associated with a 
previous history of exposure to anti-TB drugs, 
which needs urgent revision of prevention policy-
in the modality of preventing the occurrence and 
transmission of resistant TB strains. Furthermore, 
primary treatment needs to be given special 
emphasis, including sporadic screening for drug 
sensitivity before initiating treatment, and 
establishing a TB strains database for tracing and 
in-depth molecular studies. The direct observation 
therapy, short course program (DOTS), which is 
ascribed as one of the reasons for low drug-
resistant TB prevalence in SSA
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